secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-103983
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q2 net loss $247.8M; advances Phase 3 RAS trials; $2B Royalty Pharma deal
--------------------------------------------------------------------------------

- Net loss $247.8M vs $133.2M YoY; R&D expenses rose to $224.1M; FY2025 net loss guidance $1.03B-$1.09B.
- FDA Breakthrough Therapy Designation for daraxonrasib (KRAS G12C PDAC) and elironrasib (KRAS G12C NSCLC).
- Entered $2B flexible funding agreement with Royalty Pharma; first $250M tranche received; cash $2.1B.
- RASolute 302 Phase 3 trial for PDAC enrollment to complete this year; data readout expected 2026.
- Plans to initiate registrational trials for first-line PDAC and adjuvant PDAC in 2025; Phase 3 for first-line NSCLC in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017025103983/0000950170-25-103983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017025103983/rvmd-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer